|
1
|
Davies J, Patel M, Gridelli C, de Marinis
F, Waterkamp D and McCusker ME: Real-world treatment patterns for
patients receiving second-line and third-line treatment for
advanced non-small cell lung cancer: A systematic review of
recently published studies. PLoS One. 12:e01756792017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang T, Qiao M, Zhou F, Ren S, Su C and
Zhou C: Effect of combined therapy inhibiting EGFR and VEGFR
pathways in non-small-cell lung cancer on progression-free and
overall survival. Clin Lung Cancer. 18:421–431.e3. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takeda M and Nakagawa K: Toxicity profile
of epidermal growth factor receptor tyrosine kinase inhibitors in
patients with epidermal growth factor receptor gene
mutation-positive lung cancer. Mol Clin Oncol. 6:3–6. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han W and Du Y: Recent development of the
second and third generation irreversible epidermal growth factor
receptor inhibitors. Chem Biodivers. 14:2017. View Article : Google Scholar :
|
|
6
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu CQ, da Cunha Santos G, Ding K,
Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire
JA, et al: Role of KRAS and EGFR as biomarkers of response to
erlotinib in national cancer institute of canada clinical trials
group study BR.21. J Clin Oncol. 26:4268–4275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jeung YJ, Kim HG, Ahn J, Lee HJ, Lee SB,
Won M, Jung CR, Im JY, Kim BK, Park SK, et al: Shikonin induces
apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1
signaling antagonized by p300. Biochim Biophys Acta.
1863:2584–2593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou Z, Lu B, Wang C, Wang Z, Luo T, Piao
M, Meng F, Chi G, Luo Y and Ge P: RIP1 and RIP3 contribute to
shikonin-induced DNA double-strand breaks in glioma cells via
increase of intracellular reactive oxygen species. Cancer Lett.
390:77–90. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Komi Y, Suzuki Y, Shimamura M, Kajimoto S,
Nakajo S, Masuda M, Shibuya M, Itabe H, Shimokado K, Oettgen P, et
al: Mechanism of inhibition of tumor angiogenesis by
beta-hydroxyisovalerylshikonin. Cancer Sci. 100:269–277. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang W, Cai A, Chen G, Xi H, Wu X, Cui J,
Zhang K, Zhao X, Yu J, Wei B and Chen L: Shikonin induces
mitochondria-mediated apoptosis and enhances chemotherapeutic
sensitivity of gastric cancer through reactive oxygen species. Sci
Rep. 6:382672016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gara RK, Srivastava VK, Duggal S, Bagga
JK, Bhatt M, Sanyal S and Mishra DP: Shikonin selectively induces
apoptosis in human prostate cancer cells through the endoplasmic
reticulum stress and mitochondrial apoptotic pathway. J Biomed Sci.
22:262015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li W, Liu J, Jackson K, Shi R and Zhao Y:
Sensitizing the therapeutic efficacy of taxol with shikonin in
human breast cancer cells. PLoS One. 9:e940792014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song J, Zhao Z, Fan X, Chen M, Cheng X,
Zhang D, Wu F, Ying X and Ji J: Shikonin potentiates the effect of
arsenic trioxide against human hepatocellular carcinoma in vitro
and in vivo. Oncotarget. 7:70504–70515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Q, Kretschmer N, Bauer R and Efferth
T: Shikonin and its derivatives inhibit the epidermal growth factor
receptor signaling and synergistically kill glioblastoma cells in
combination with erlotinib. Int J Cancer. 137:1446–1456. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X, Fan XX, Jiang ZB, Loo WT, Yao XJ,
Leung EL, Chow LW and Liu L: Shikonin inhibits gefitinib-resistant
non-small cell lung cancer by inhibiting TrxR and activating the
EGFR proteasomal degradation pathway. Pharmacol Res. 115:45–55.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li YL, Sun J, Hu X, Pan YN, Yan W, Li QY,
Wang F, Lin NM and Zhang C: Epothilone B induces apoptosis and
enhances apoptotic effects of ABT-737 on human cancer cells via
PI3K/AKT/mTOR pathway. J Cancer Res Clin Oncol. 142:2281–2289.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang C, Shi J, Mao SY, Xu YS, Zhang D,
Feng LY, Zhang B, Yan YY, Wang SC, Pan JP, et al: Role of p38 MAPK
in enhanced human cancer cells killing by the combination of
aspirin and ABT-737. J Cell Mol Med. 19:408–417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niu FY and Wu YL: Novel agents and
strategies for overcoming EGFR TKIs resistance. Exp Hematol Oncol.
3:22014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Engelman JA and Jänne PA: Mechanisms of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res.
14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li YL, Pan YN, Wu WJ, Mao SY, Sun J, Zhao
YM, Dong JY, Zhang DY, Pan JP, Zhang C and Lin NM: Evodiamine
induces apoptosis and enhances apoptotic effects of erlotinib in
wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition. Med
Oncol. 33:162016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oxnard GR, Thress KS, Alden RS, Lawrance
R, Paweletz CP, Cantarini M, Yang JC, Barrett JC and Jänne PA:
Association between plasma genotyping and outcomes of treatment
with osimertinib (AZD9291) in advanced non-small-cell lung cancer.
J Clin Oncol. 34:3375–3382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suda K, Rivard CJ, Mitsudomi T and Hirsch
FR: Overcoming resistance to EGFR tyrosine kinase inhibitors in
lung cancer, focusing on non-T790M mechanisms. Expert Rev
Anticancer Ther. 17:779–786. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hsieh YS, Liao CH, Chen WS, Pai JT and
Weng MS: Shikonin inhibited migration and invasion of human lung
cancer cells via suppression of c-Met-mediated
epithelial-to-mesenchymal transition. J Cell Biochem.
118:4639–4651. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gwon SY, Ahn JY, Jung CH, Moon BK and Ha
TY: Shikonin suppresses ERK 1/2 phosphorylation during the early
stages of adipocyte differentiation in 3T3-L1 cells. BMC Complement
Altern Med. 13:2072013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Regales L, Gong Y, Shen R, de Stanchina E,
Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O,
Mellinghoff IK, et al: Dual targeting of EGFR can overcome a major
drug resistance mutation in mouse models of EGFR mutant lung
cancer. J Clin Invest. 119:3000–3010. 2009.PubMed/NCBI
|
|
28
|
Jean-Philippe J, Paz S and Caputi M: hnRNP
A1: The Swiss army knife of gene expression. Int J Mol Sci.
14:18999–19024. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yin SY, Efferth T, Jian FY, Chen YH, Liu
CI, Wang AH, Chen YR, Hsiao PW and Yang NS: Immunogenicity of
mammary tumor cells can be induced by shikonin via direct
binding-interference with hnRNPA1. Oncotarget. 7:43629–43653.
2016.PubMed/NCBI
|
|
30
|
Cammas A, Lacroix-Triki M, Pierredon S, Le
Bras M, Iacovoni JS, Teulade-Fichou MP, Favre G, Roché H, Filleron
T, Millevoi S and Vagner S: hnRNP A1-mediated translational
regulation of the G quadruplex-containing RON receptor tyrosine
kinase mRNA linked to tumor progression. Oncotarget. 7:16793–16805.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu DW, Chen TC, Huang HS and Lee H:
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently
overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Cell Death Dis. 7:e22902016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sano R and Reed JC: ER stress-induced cell
death mechanisms. Biochim Biophys Acta. 1833:3460–3470. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Corazzari M, Gagliardi M, Fimia GM and
Piacentini M: Endoplasmic reticulum stress, unfolded protein
response, and cancer cell fate. Front Oncol. 7:782017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Terai H, Kitajima S, Potter DS, Matsui Y,
Quiceno LG, Chen T, Kim TJ, Rusan M, Thai TC, Piccioni F, et al: ER
stress signaling promotes the survival of cancer ‘persister cells’
tolerant to EGFR tyrosine kinase inhibitors. Cancer Res.
78:1044–1057. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Malhotra JD and Kaufman RJ: Endoplasmic
reticulum stress and oxidative stress: A vicious cycle or a
double-edged sword? Antioxid Redox Signal. 9:2277–2293. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rutkowski DT and Kaufman RJ: That which
does not kill me makes me stronger: Adapting to chronic ER stress.
Trends Biochem Sci. 32:469–476. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Verfaillie T, Rubio N, Garg AD, Bultynck
G, Rizzuto R, Decuypere JP, Piette J, Linehan C, Gupta S, Samali A
and Agostinis P: PERK is required at the ER-mitochondrial contact
sites to convey apoptosis after ROS-based ER stress. Cell Death
Differ. 19:1880–1891. 2012. View Article : Google Scholar : PubMed/NCBI
|
